

Flavored Oral Suspending Vehicle



ORA-Blend® is a flavored oral suspending vehicle used to simplify the process involved in the extemporaneous compounding of oral suspensions. Medicated powder can be incorporated into ORA-Blend® to form elegant, uniform and physically stable suspensions.

Applications

ORA-Blend® combines the suspending properties of ORA-Plus® with the flavoring agents of ORA-Sweet® and is ideal for:

- Pediatric suspensions
- Geriatric suspensions

Properties

ORA-Blend® is an aqueous-based sweetened vehicle consisting of a synergistic blend of suspending agents that have a high degree of colloidal activity. The suspending agents form a structured, gel-like matrix which suspends particles and allow for little settling. ORA-Blend® is buffered to a slightly acidic pH to help reduce degradation of medicinal agents through oxidation. An anti-foam agent is incorporated in ORA-Blend® to allow for vigorous shaking with minimal foam.

Contains:

Purified water, sucrose, glycerin, sorbitol, berry citrus flavor, microcrystalline cellulose, carboxymethylcellulose sodium, xanthan gum, carrageenan, calcium sulfate, trisodium phosphate, citric acid and sodium phosphate as buffers, dimethicone antifoam emulsion. Preserved with methylparaben and potassium sorbate.

Specifications

Appearance: Cloudy liquid

pH: Approximately 4.0 - 4.5

Taste: Sweet citrus-berry flavor

Viscosity: Approximately 700 cps at 25°C via Brookfield viscometer

Osmolality: 1665 mOsm/kg

Available through your wholesaler or distributor.

Compounding Examples



ADDERALL® 1 mg/mL, 100 mL³

Adderall 10 mg/tablet	10 tablets
ORA-Blend®	q.s. 100 mL

- Expiration 30 days at 25°C
- Protect from light
- Shake well before using

TIAGABINE 1 mg/mL, 120 mL⁴

Tiagabine 12 mg/tablet	10 tablets
ORA-Blend®	q.s. 120 mL

- Expiration 70 days at 25°C or 91 days at 4°C
- Protect from light
- Shake well before using

TERBINAFINE HYDROCHLORIDE 25 mg/mL, 100 mL²

Terbinafine HCl 250 mg/tablet	10 tablets
ORA-Blend®	q.s. 100 mL

- Expiration 42 days at either 4°C or 25°C
- Protect from light
- Shake well before using

VALGANCICLOVIR 30 mg/mL, (as the HCl salt), 90 mL¹

Valganciclovir 450 mg/tablet	6 tablets
ORA-Blend®	q.s. 90 mL

- Expiration 35 days at 4°C
- Protect from light
- Shake well before using

General Directions for Compounding ORA-Blend® Suspensions

- Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples to the left.) *It may be wise to add approximately 10% overage for compounding losses.*
- Crush tablets with a mortar and pestle to a fine powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.
- Add a small amount of **ORA-Blend®** and triturate to a thick, smooth paste. Add the remainder of the **ORA-Blend®** by geometric dilution.
- Mix briefly with a mortar and pestle until a uniform suspension is formed.
- Dispense in a tight, light resistant amber bottle with appropriate labeling.
- Label with an expiration date. *If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.*
- Depending on the medicinal agent used, label containers "Shake Well Before Using", "Protect From Light", and "Keep Refrigerated".

¹American Journal of Health-System Pharmacists 2003; 60:687-90.

²American Journal of Health-System Pharmacists 1999; 56:243-5.

³American Journal of Health-System Pharmacists 2001; 58:1418-21.

⁴American Journal of Health-System Pharmacists 2003; 60:75-7.

Contraindications

ORA-Blend® is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.

DISCLAIMER:

All information presented is intended to demonstrate the application of Padagis® vehicles in compounding. The information and examples provided in this paper have not been evaluated by the Food and Drug Administration and are provided for educational purposes only. Any information and examples provided are not intended to replace the advice of a physician or take the place of good pharmaceutical compounding practices. The preparation, dispensing, and administration of pharmaceuticals is the responsibility of licensed medical professionals and must adhere to current pharmaceutical compounding requirements and lawful practice of medicine. Padagis® assumes no liability for any injury and/or damage to persons from use of any information and/or examples contained in this document. Padagis® does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process. Vehicle purchasers assume all risks of patent infringement by reason of any such use, combination or operation. Before compounding any prescription drug with Padagis® vehicles, please review the full prescribing information of the prescription drug for important safety information and limitations of use.